Ant Group Extends Partnership with Olympic Tennis Champion Qinwen Zheng as Brand Ambassador
Ant Group today announced the extension of its successful partnership with Qinwen Zheng, the rising tennis legend and Olympic gold medalist. This renewed collaboration underscores the shared commitment to striving for excellence, while inspiring and engaging young people together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109266663/en/
(Photo: Business Wire)
“I am excited to continue my partnership with Ant Group as a brand ambassador,” said Zheng. “Ant Group's unwavering commitment to inclusivity and equal development opportunities for diverse groups, particularly women and teenagers, aligns perfectly with my values. I look forward to our next chapter together to inspire even more young people to pursue their dreams.”
In 2024, Zheng made history by winning the gold medal in women's singles at the Paris Olympics, becoming the first Asian tennis player to secure an Olympic singles title. Her perseverance, courage, and optimistic spirit on the court make her a role model for younger generations.
So far, Zheng has amassed four WTA Tour titles, one WTA Challenger title, and eight ITF singles titles, and was honored as the 2022 WTA Newcomer of the Year. She also contested a major final at the 2024 Australian Open.
“Over the past two years, Qinwen Zheng’s remarkable achievements have encouraged young people not only in China but around the world,” said Ray Chan, Chief Marketing Officer of Ant Group and Vice Chairman of Ant Foundation. “Through this renewed partnership and leveraging our innovative technologies and platforms, we will further promote equal and sustainable development opportunities for youth across rural and urban areas, motivating and supporting them to pursue their dreams in sport and beyond.”
Ant Group initiated its partnership with Zheng in 2022. Prior to that, Ant Group also named Wang Shuang, a top female footballer, as another brand ambassador and together inspire teenagers playing football in rural areas to chase their dreams.
About Ant Group
Ant Group traces its roots back to Alipay, which was established in 2004 to create trust between online sellers and buyers. Over the years, Ant Group has grown to become one of the world's leading open Internet platforms. Through technological innovation, Ant Group supports its partners in providing inclusive, convenient digital life and digital financial services to consumers and SMEs. In addition, it has been introducing new technologies and products to support the digital transformation of industries and facilitate industrial collaboration. Working together with global partners, the company enables merchants and consumers to make and receive payments and remit around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109266663/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces Pricing of Underwritten Offering10.1.2025 13:01:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant (“ADS Warrant”) to purchase one ADS, which has an exercise price of $5.796 per ADS, representing a 40% premium to the last sale price and will be exercisable following a specified data milestone. The offering price is $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and accompanying ADS Warrant. All of the securities are to be sold by Compass. The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions. The offering was led by Deep Track Capital and included participation
Ronald S. Lauder to Retire from The Estée Lauder Companies’ Board of Directors10.1.2025 12:45:00 CET | Press release
Eric Zinterhofer to join the Company’s Board of Directors The Estée Lauder Companies (NYSE: EL) announced today that Ronald S. Lauder will retire from the Company’s Board of Directors (the “Board”) effective immediately. Pursuant to the stockholders’ agreement among Lauder family members and the Company, Mr. Lauder has the right to designate two directors of the Company. His daughter Jane Lauder will continue to serve on the Board in her current position, and he has named his son-in-law Eric Zinterhofer, who is married to his daughter Aerin Lauder, to be his second designee. In connection with Mr. Lauder’s retirement from the Board and his designation of Mr. Zinterhofer as his nominee, the Board has elected Mr. Zinterhofer effective immediately. Mr. Lauder will remain Chairman of Clinique Laboratories, LLC. Mr. Zinterhofer joins the Board with extensive financial, investing and global business experience, and is currently a Founding Partner of Searchlight Capital Partners. He serves on
GlobalLogic Announces Leadership Change: Srini Shankar Appointed as President and Chief Executive Officer10.1.2025 11:30:00 CET | Press release
GlobalLogic Inc., a Hitachi Group Company and leader in Digital Engineering, today announced that GlobalLogic’s Chief Business Officer (CBO) and Head of Global Industries, Srinivas (Srini) Shankar has been appointed its new President and CEO, effective February 3, 2025. Srini will succeed Nitesh Banga, who has decided to step down to pursue new opportunities outside of Hitachi and GlobalLogic. Nitesh joined GlobalLogic in June 2018. His leadership and expertise helped GlobalLogic achieve significant organic and inorganic growth, expand the organization’s offerings, capabilities, and footprint, and evolve as a global leader in Design-Led Digital Engineering. Nitesh also played a central role in GlobalLogic’s acquisition by Hitachi and has been paramount to the ongoing synergy success between GlobalLogic and Hitachi, including the expansion of GlobalLogic's business in Japan. “I am proud of the significant growth we achieved, the purposeful impact we’ve engineered for our clients and the
Yagi & Co., Ltd.: New Material “LAVATECH” Containing Lava from Mt. Fuji to Be Exhibited at Heimtextil 202510.1.2025 04:00:00 CET | Press release
LAVATECH, which has a high far-infrared effect, to be unveiled for the first time at an international trade fair for home textiles and contract textiles Yagi & Co., Ltd. (TOKYO:7460) (https://www.yaginet.co.jp/en/index.html) will unveil LAVATECH for the first time at the Heimtextil Exhibition in Germany (an international trade fair for home textiles and contract textiles). LAVATECH, which boasts a high far-infrared effect, is made by using special technology to finely crush lava rock found in the ground around Mt. Fuji for weaving into fibers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250110677601/en/ Mt. Fuji (Photo: Business Wire) About LAVATECH Since ancient times, the lava rock formed beneath Mt. Fuji has been carefully protected from changes in surface temperature and weathering. LAVATECH is made by weaving this high-quality underground lava rock. We have achieved a high far-infrared effect by using a special techn
Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy10.1.2025 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announced that the company has concluded an investment agreement with MPM BioImpact LLC, a Boston-based biotech investment firm (hereafter “MPM BioImpact”). Meiji has committed to invest USD 20 million in MPM BioImpact’s new technologies and virology strategy as a strategic partner and aims to broaden Meiji’s perspective on early-stage opportunities and enhance its global network. MPM BioImpact is a world-leading biotechnology investment firm with three decades of experience in creating and investing in innovative companies and aims to deliver transformative therapies to patients. The firm invests in both private and public companies, providing a unique and longitudinal view of drug development across the industry. Its experienced and dedicated team of investment professionals, entrepreneurs, advisors, and leading scientists seeks to translate scientific
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom